Table 2 Clinical outcome/Survival analysis with Principal components and without or with SUVmax.

From: Radiomics analysis at PET/CT contributes to prognosis of recurrence and survival in lung cancer treated with stereotactic body radiotherapy

 

OS

RFP

DC

RC

DSS

Without SUVmax

(HR [CI]),

p value

PC 4

0.45 [0.26–0.78],

p = 0.004

SEX

2[[1.11–3.62],

p = 0.02

PC 4

0.51 [0.28–0.91],

p = 0.02

PC 4

0.38 [0.17–0.83],

p = 0.02

PC 2

1.34 [0.09–17.88]

p = 0.03

PC 3

0.74 [0.58–0.96],

p = 0.02

PC 1

1.08 [1.00–1.17],

p = 0.04

PC 1

1.12 [1.02–1.23],

p = 0.01

 

PC 3

0.64 [0.43–0.94]

p = 0.02

With SUVmax

(HR [CI]),

p value

PC 4

0.45 [0.26–0.78],

p = 0.004

SEX

2.06 [1.14–3.73],

p = 0.02

PC 4

0.5 [0.28–0.91],

p = 0.02

PC 4

0.38 [0.17–0.83],

p = 0.02

PC 2

1.34 [0.09–17.88]

p = 0.03

PC 3

0.74 [0.58–0.96],

p = 0.02

SUV

1.1 [1.03–1.18],

p = 0.04

SUV

1.13 [1.04–1.22],

p = 0.002

 

PC 3

0.64 [0.43–0.94]

p = 0.02

  1. OS: Overall survival, RFP: Recurrence free probability, DC: Distant control, RC: Regional control, DSS: Disease specific survival.
Back to article page